Alpha 2.0
Login Register
» Authors » Peter L Abrams

Peter L Abrams

Explore the profile of Peter L Abrams including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 19
Followers 0
Related Specialties
General Surgery
General Medicine
Top 10 Co-Authors
Raja Kandaswamy
Robert C Harland
Oyedolamu K Olaitan
Robert J Stratta
Camillo Ricordi
Piotr Witkowski
Kenneth A Andreoni
Matthew Cooper
Chirag S Desai
R Paul Robertson
Published In
Clin Transplant
J Clin Med
Am J Transplant
J Surg Res
Adv Wound Care (New Rochelle)
Affiliations
Soon will be listed here.
Recent Articles
1.
An Initial Analysis of the Baseline Levels of Dd-cfDNA After Pancreas Transplantation: A Prospective Study From High-volume Centers in the United States
Yoo A, Riedel A, Qian I, Bartosic A, Soltani R, Kibria G, et al.
Transplant Direct . 2023 Mar; 9(4):e1459. PMID: 36935870
Methods: One hundred eighty-one dd-cfDNA samples (n) were collected from 77 patients (N) up to 132 mo posttransplant. Results: The median dd-cfDNA level among all subjects was 0.28% (0.13%, 0.71%)....
2.
Interfacility Transfer for Nonelective Cholecystectomy in High MELD Patients: An ACS-NSQIP Analysis
Turcotte J, Weltz A, Bussey I, Abrams P, Feather C, Klune J
J Surg Res . 2022 Jun; 279:127-134. PMID: 35759930
Introduction: Interfacility transfer to a referral center is often considered for patients with liver disease undergoing nonelective cholecystectomy given management complexities and perioperative risk. We sought to determine the association...
3.
Arguments against the Requirement of a Biological License Application for Human Pancreatic Islets: The Position Statement of the Islets for US Collaborative Presented during the FDA Advisory Committee Meeting
Witkowski P, Odorico J, Pyda J, Anteby R, Stratta R, Schrope B, et al.
J Clin Med . 2021 Jul; 10(13). PMID: 34209541
The Food and Drug Administration (FDA) has been regulating human islets for allotransplantation as a biologic drug in the US. Consequently, the requirement of a biological license application (BLA) approval...
4.
Surgical Management of Lower Extremity Wounds in the Solid Organ Transplant Patient Population: Surgeon Beware
Abu El Hawa A, Bekeny J, Dekker P, Zolper E, Tirrell A, Kennedy C, et al.
Adv Wound Care (New Rochelle) . 2021 Jan; 11(1):10-18. PMID: 33487096
To evaluate our institutional outcomes of surgical management of lower extremity (LE) wounds in the solid organ transplant recipient population. An 8-year retrospective review was conducted for all solid organ...
5.
The demise of islet allotransplantation in the United States: A call for an urgent regulatory update
Witkowski P, Philipson L, Kaufman D, Ratner L, Abouljoud M, Bellin M, et al.
Am J Transplant . 2020 Nov; 21(4):1365-1375. PMID: 33251712
Islet allotransplantation in the United States (US) is facing an imminent demise. Despite nearly three decades of progress in the field, an archaic regulatory framework has stymied US clinical practice....
6.
The incidence of fungal infections in pancreas transplant recipients in the absence of systemic antifungal prophylaxis
Shaikh S, Zimmerman A, Nolan A, Cooper M, Abrams P
Clin Transplant . 2019 Aug; 33(10):e13691. PMID: 31400149
Background: There is a lack of high-level evidence identifying meaningful outcomes and the place in therapy for systemic perioperative antifungal prophylaxis (ppx) in pancreas transplant recipients. As our program does...